| Symbol | HTR3D |
|---|---|
| Full Name | 5-Hydroxytryptamine Receptor 3D |
| Chromosomal Location | 3q27.1 |
| NCBI Gene ID | 200373 |
| OMIM ID | 610122 |
| Ensembl ID | ENSG00000165644 |
| UniProt ID | Q8WXA1 |
| Protein Size | 473 amino acids |
| Protein Family | Cys-loop ligand-gated ion channel superfamily |
| Expression | Brain (neurons, interneurons), peripheral nervous system, immune cells |
HTR3D (5-Hydroxytryptamine Receptor 3D) is a member of the ligand-gated ion channel family that forms part of the 5-HT3 receptor. Unlike other 5-HT receptors that are G protein-coupled receptors (GPCRs), the 5-HT3 receptor is a Cys-loop ion channel that mediates fast, depolarizing responses to serotonin[1]. The HTR3D gene encodes the subunit D (5-HT3D), which combines with other 5-HT3 subunits (primarily HTR3A) to form functional receptor complexes.
The 5-HT3 receptor is unique among serotonin receptors because it functions as a ligand-gated ion channel rather than a GPCR. This makes it pharmacologically distinct and clinically important—5-HT3 antagonists are widely used as antiemetics in chemotherapy-induced nausea and have potential applications in various neurological and psychiatric conditions.
This page provides comprehensive information on the HTR3D gene, including its molecular biology, physiological functions, disease associations, and therapeutic relevance.
The HTR3D gene is located on chromosome 3q27.1, within a cluster of 5-HT3 receptor subunit genes. This genomic region has undergone duplication events during evolution, giving rise to multiple 5-HT3 subunit genes (HTR3A, HTR3B, HTR3C, HTR3D, HTR3E) with distinct but overlapping expression patterns.
The 5-HT3 receptor family belongs to the Cys-loop ligand-gated ion channel superfamily, which includes nicotinic acetylcholine receptors (nAChRs), GABA_A receptors, and glycine receptors. These receptors share a common architecture of five subunits that form a central ion channel pore. The 5-HT3 receptors likely evolved from an ancestral nAChR-like gene through diversification of ligand-binding specificity.
The 5-HT3D subunit, like other Cys-loop receptor subunits, contains:
The 5-HT3 receptor functions as a pentameric assembly. The most common composition is a homomeric assembly of HTR3A subunits, but heteromeric assemblies incorporating HTR3B, HTR3C, HTR3D, and HTR3E subunits produce receptors with distinct pharmacological and biophysical properties[2].
The incorporation of HTR3D into heteromeric receptors can alter:
The 5-HT3 receptor is a cationic channel that conducts sodium (Na+) and potassium (K+), with a reversal potential near 0 mV. Activation produces a rapidly rising inward current that depolarizes neurons, making it an excitatory receptor. The channel has:
HTR3D expression in the brain is more restricted than HTR3A[3]:
HTR3D is also expressed in:
Expression of HTR3D shows developmental regulation[4]:
The primary function of 5-HT3 receptors containing HTR3D is to mediate fast, ionotropic responses to serotonin. Unlike the more common 5-HT GPCRs that signal through second messengers, 5-HT3 receptors provide rapid excitatory signals:
5-HT3 receptors influence the release of other neurotransmitters:
In the spinal cord dorsal horn, 5-HT3 receptors (including those containing HTR3D subunits) are located on primary sensory afferents and interneurons[6]. They contribute to:
High expression of 5-HT3 receptors in the gut underlies their well-known antiemetic function:
5-HT3 antagonists (e.g., alosetron) are approved for IBS with predominant diarrhea[7]. HTR3D expression in enteric neurons makes it relevant to:
The primary clinical use of 5-HT3 antagonists is preventing chemotherapy-induced nausea. While HTR3A is the primary subunit in most antiemetic effects, HTR3D contribution to receptor diversity may influence:
5-HT3 receptors have been implicated in schizophrenia pathophysiology[8]:
The role of 5-HT3 receptors in mood disorders is complex:
Emerging evidence links 5-HT3 receptors to neurodegenerative conditions[9]:
5-HT3 receptors may play a role in seizure disorders:
Clinical trials have explored 5-HT3 antagonists for cognitive improvement in schizophrenia and AD[10]:
Novel approaches targeting 5-HT3 receptors include[11]:
Genetic variation in HTR3 genes can influence drug response[12]:
For more information, see:
The HTR3D gene encodes a subunit of the 5-HT3 receptor, a ligand-gated ion channel that mediates fast serotonergic signaling. While HTR3A is the primary subunit forming functional receptors, HTR3D contributes to receptor diversity and can modulate receptor properties when incorporated into heteromeric assemblies.
The 5-HT3 receptor's role as the only ionotropic serotonin receptor makes it pharmacologically unique. 5-HT3 antagonists are widely used antiemetics and have potential applications in IBS, pain, and potentially cognitive disorders. Understanding HTR3D's contribution to receptor function may help explain individual variation in drug response and guide development of more selective therapeutics.
Continued research into the structure, function, and therapeutic potential of 5-HT3 receptors containing HTR3D promises to yield new insights into serotonergic signaling and novel treatments for neurological and psychiatric conditions.
Barnes NM, Hales TG, Lummis SC, et al. The 5-HT3 receptor - the relationship between structure, function, and pharmacology. Pharmacol Ther. 2019. ↩︎
Davies PA, Pistis M, Hanna KA, et al. The 5-HT3B subunit: a new class of 5-HT3 receptor. Nature. 1999. ↩︎
Locker M, Beaumont E, Lanoir J, et al. 5-HT3 receptor expression in the central nervous system. Cell Tissue Res. 2020. ↩︎
Nakamura T, Bhatt S, Shimazoe T, et al. 5-HT3 receptor subunit expression in mouse brain during development. Dev Brain Res. 2013. ↩︎
Engel M, Smolinski M, Fiebach O, et al. 5-HT3 receptor-mediated dopamine release in the nucleus accumbens. Psychopharmacology. 2013. ↩︎
Marcoli M, Raiteri L,longo G, et al. 5-HT3 receptors on central terminals of sensory afferents mediate pain transmission. Pain. 2008. ↩︎
Jones KA, Peters T, Bailey C, et al. Naluzel for the treatment of irritable bowel syndrome: clinical efficacy and safety. Gastroenterology. 2008. ↩︎
Farber NB, Newcomer JW, Olney JW. The 5-HT3 receptor in schizophrenia: therapeutic implications. Expert Opin Ther Targets. 2002. ↩︎
Schwartz PJ, Lankford C, Mogg K, et al. 5-HT3 receptors, mood, and neurodegeneration: potential therapeutic targets. CNS Drugs. 2011. ↩︎
Turner EH, Blackwell SE, Harmer C, et al. 5-HT3 antagonists in cognitive disorders: a systematic review. J Psychopharmacol. 2019. ↩︎
Gupta R, Kumar P, Sethi M, et al. Novel 5-HT3 receptor modulators for neurological applications. Bioorg Med Chem. 2023. ↩︎
Hollands C, Bradbury J, McQuade R, et al. Association between 5-HT3 receptor gene polymorphisms and neuropsychiatric disorders. J Psychiatr Res. 2020. ↩︎